Loading...
GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition
EP-100 is a synthetic lytic peptide that specifically targets the gonadotropin-releasing hormone receptor on cancer cells. To extend the utility of EP-100, we aimed to identify effective combination therapies with EP-100 for ovarian cancer and explore potential mechanisms of this combination. A seri...
Na minha lista:
| Udgivet i: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6497555/ https://ncbi.nlm.nih.gov/pubmed/30926640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0770 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|